Form 4: Cerus Corp CEO William Greenman Reports Stock Transactions

William Greenman, President and CEO of Cerus Corporation, reports the acquisition of shares through restricted stock units and the sale of shares to cover tax obligations.

Summary

• On March 3, 2025, William Greenman, the President and CEO of Cerus Corporation, acquired 57,637 shares of common stock through the vesting of restricted stock units.
• On March 4, 2025, Greenman sold 23,023 shares of common stock at a weighted average price of $1.5485 per share.
• The sale was intended to cover statutory tax withholding obligations and brokerage fees related to the vesting of the restricted stock units.
• Following these transactions, Greenman directly owns 3,230,000 shares of Cerus Corporation common stock.
• This total includes 6,405 and 7,700 shares purchased under the Issuer's Employee Stock Purchase Plan on August 30, 2024 and February 28, 2025 respectively.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisition of shares is a positive sign, but the sale, even for tax purposes, tempers the overall sentiment. The transactions appear routine and well-explained.

Positives

• The acquisition of shares through restricted stock units indicates confidence in the company's future performance.

Negatives

• The sale of shares, even if for tax purposes, could be perceived negatively by some investors.

Risks

• Sales of shares by company executives, even for tax purposes, can sometimes create short-term price volatility.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Sales to cover tax obligations are common and generally not viewed as a negative signal if properly disclosed.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, such as Cerus, to receive stock options and restricted stock units as part of their compensation packages.
• The sale of shares to cover tax obligations is a standard practice among executives who receive equity compensation.
• Companies like Gilead Sciences or Amgen, which also operate in the biotechnology sector, often see similar patterns of insider transactions related to equity compensation.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.

Key Dates